BioMerieux Q1 Sales Down 3.9% On Organic Basis; Revises 2026 Guidance

BioMerieux reported first-quarter consolidated sales of 984 million euros, down 10.4% as reported and 3.9% organically from last year. Management attributed the decline to a weaker respiratory season versus the prior year, indicating a temporary demand headwind rather than a structural issue.

Analysis

BioMerieux reported first-quarter consolidated sales of 984 million euros, down 10.4% as reported and 3.9% organically from last year. Management attributed the decline to a weaker respiratory season versus the prior year, indicating a temporary demand headwind rather than a structural issue.